Eli Lilly and Company announced the approval of U.S Food and Drug Administration (FDA) for Retevmo the first medicine particularly approved for the treatment of adult patients with metastatic RET-mutant medullary thyroid cancer. Approval based on results from the largest patient trial yet reported in RET-driven malignancies, LIBRETTO-001 Phase 1/2
Quest Diagnostics introduces the very first virtual preventive care service through QuestDirect that is customizable for men and women and gives a health quotient score that can be monitored over time. It uses biometric screening and does a health risk assessment.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?